Name | T 0156 hydrochloride |
---|---|
Synonyms |
Methyl 2-[(2-methylpyridin-4-yl)methyl]-1-oxo-8-(pyrimidin-2-ylmethoxy)-4-(3,4,5-trimethoxyphenyl)-1,2-dihydro-2,7-naphthyridine-3-carboxylate hydrochloride (1:1)
2,7-Naphthyridine-3-carboxylic acid, 1,2-dihydro-2-[(2-methyl-4-pyridinyl)methyl]-1-oxo-8-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) MFCD03453030 Methyl 2-[(2-methyl-4-pyridinyl)methyl]-1-oxo-8-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-1,2-dihydro-2,7-naphthyridine-3-carboxylate hydrochloride (1:1) |
Description | T-0156 is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. T-0156 specifically inhibits the hydrolysis of cyclic guanosine monophosphate (cGMP) by PDE5 in a competitive manner (IC50=0.23 nM). T-0156 inhibits PDE6 (IC50=56 nM) and has low potencies against PDE1, PDE2, PDE3, and PDE4 (IC50>10 μM). T-0156 enhances the nitric oxide (NO)/cGMP pathway[1]. |
---|---|
Related Catalog | |
Target |
PDE5:0.23 nM (IC50) PDE1:>100 μM (IC50) PDE2:>100 μM (IC50) PDE3:>100 μM (IC50) PDE4:63 μM (IC50) PDE6:56 nM (IC50) |
In Vitro | T-0156 at 10 and 100 nM increases cGMP levels, causing relaxation of the tissue in the isolated rabbit corpus cavernosum[1]. |
References |
Molecular Formula | C31H30ClN5O7 |
---|---|
Molecular Weight | 620.05 |
Exact Mass | 619.183350 |